SXL
CRSP icon

Summit X LLC’s CRISPR Therapeutics CRSP Stock Holding History

Summit X LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-575
Closed -$335 – 287
2020
Q3 		$335 Buy
+575
New +$51K 0.01% 350

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summit X LLC's CRSP Position: Q4 2020 in Review

Summit X LLC sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 575 shares — an estimated $335 sold.

Summit X LLC first reported a position in CRSP in Q3 2020 and held it in 1 quarter. The position peaked at $335 in Q3 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Summit X LLC reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Summit X LLC sold 575 CRISPR Therapeutics shares in Q4 2020, an estimated $335.
  • Summit X LLC first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 1 quarter.
  • Summit X LLC's CRISPR Therapeutics position peaked at $335 in Q3 2020.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Summit X LLC's 13F filing for Q4 2020, filed 29 Jan 2021.